The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Evaluation of pan‐ TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis‐like neural tumour and histological mimics
Abstract
Aims: Infantile fibrosarcoma is characterised by intersecting fascicles of spindle cells and ETV 6 – NTRK 3 gene fusion in most cases. Given histological overlap with other spindle‐cell tumours, the diagnosis can be challenging and often requires molecular confirmation. A recently developed pan‐ TRK antibody shows promise for identifying tumours with NTRK fusions. The purpose of this study was to evaluate the potential diagnostic utility of pan‐ TRK immunohistochemistry for infantile fibrosarcoma. Methods and results: We evaluated whole‐tissue sections from 210 cases, including 15 infantile fibrosarcomas; five each lipofibromatosis‐like neural tumour and lipofibromatosis; 10 each primitive myxoid mesenchymal tumour of infancy ( PMMTI ) and low‐grade myofibroblastic sarcoma; 15 each fibrous hamartoma of infancy ( FHI ), myofibroma/myofibromatosis and desmoid‐type fibromatosis; and 20 each low‐grade fibromyxoid sarcoma, synovial sarcoma, spindle‐cell rhabdomyosarcoma, malignant peripheral nerve sheath tumour, fibrosarcomatous dermatofibrosarcoma protuberans (F‐ DFSP ) and nodular fasciitis. Immunohistochemistry was performed using a rabbit monoclonal pan‐ TRK antibody. Immunoreactivity for pan‐ TRK was observed in all 15 (100%) infantile fibrosarcomas, including diffuse immunoreactivity (>50% of cells) in 14 (93%) cases. Pan‐ TRK was positive in all five (100%) lipofibromatosis‐like neural tumours. Of the 190 histological mimics, diffuse pan‐ TRK immunoreactivity was noted in 16 (8%) cases, including five PMMTI , five FHI (highlighting predominantly the primitive myxoid spindle‐cell components), three F‐ DFSP , one low‐grade myofibroblastic sarcoma, one myofibroma and one spindle‐cell rhabdomyosarcoma. Conclusions: Diffuse pan‐ TRK immunoreactivity is a highly sensitive but not entirely specific diagnostic marker for infantile fibrosarcoma, and may be helpful in selecting patients for TRK ‐targeted therapy. As expected, lipofibromatosis‐like neural tumours, which harbour NTRK 1 fusions, also show diffuse pan‐ TRK immunoreactivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Cited by
Molecular characterization of cancers with NTRK gene fusions
Gatalica, Z., Xiu, J., Swensen, J., & Vranic, S. (2019) · Modern Pathology · doi:10.1038/s41379-018-0118-3 · Cited by 486
Updates from the 2020 World Health Organization Classification of Soft Tissue and Bone Tumours
Anderson, W. J., & Doyle, L. A. (2021) · Histopathology · doi:10.1111/his.14265 · Cited by 286
Identifying patients with NTRK fusion cancer
Solomon, J. P., Benayed, R., Hechtman, J. F., & Ladanyi, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz384 · Cited by 270
The current state of molecular testing in the treatment of patients with solid tumors, 2019
El‐Deiry, W. S., Goldberg, R. M., Lenz, H., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21560 · Cited by 264
Metadata
- Authors
- Hung, Y. P., Fletcher, C. D. M., & Hornick, J. L.
- Venue
- Histopathology
- Publisher
- Wiley
- Published
- 2018-07-05
- Volume
- 73
- Issue
- 4
- Pages
- 634-644
- ISSN
- 0309-0167 (ISSN-L)
- 1365-2559
- OpenAlex
- W2807516814
- Cited by
- 162
- References
- 1
- FWCI
- 14.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.